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Abstract 
Background: Intracellular defense proteins, also referred to as restriction factors, are capable of interfering with dif‑
ferent steps of the viral life cycle. Among these, we have shown that Tripartite motif 22 (TRIM22) suppresses basal as 
well as phorbol ester‑induced HIV‑1 long terminal repeat (LTR)‑mediated transcription, independently of its E3 ubiq‑
uitin ligase activity, nuclear factor kappa‑light‑chain‑enhancer of activated B cells (NF‑kB) binding to the U3 region 
and Tat interaction with the TAR region of the HIV‑1 LTR. As basal HIV‑1 transcription is driven by the transcription 
factor specificity protein 1 (Sp1), we have investigated whether TRIM22 could interfere with Sp1‑driven transcriptional 
activation of the HIV‑1 LTR.
Findings: 293T cells, devoid of endogenous TRIM22 expression, were transfected with a TRIM22‑expressing plasmid 
together with reporter plasmids driven by the HIV‑1 LTR promoter either containing or lacking Sp1 binding sites or 
with reporter plasmids driven by non‑viral promoter sequences either containing or lacking the three Sp1 binding 
sites from the HIV‑1 LTR. These reporter assays showed that TRIM22 efficiently inhibited Sp1‑driven transcription. 
Knocking down TRIM22 expression in the CD4+ SupT1 T cell line increased the replication of Sp1‑dependent HIV‑1 
variants. TRIM22 did not interact with Sp1, but prevented binding of Sp1 to the HIV‑1 promoter, as demonstrated in 
protein‑DNA pull down and chromatin immunoprecipitation assays.
Conclusion: TRIM22 acts as a suppressor of basal HIV‑1 LTR‑driven transcription by preventing Sp1 binding to the 
HIV‑1 promoter.
Keywords: HIV‑1 promoter, TRIM22, Sp1‑driven transcription
© 2015 Turrini et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Findings
Tripartite Motif (TRIM) proteins form a large family 
that encompasses several members with broad antivi-
ral activities against both DNA and RNA viruses [1, 2]. 
TRIM22 has been previously shown to inhibit the rep-
lication of HIV-1 [3, 4], Influenza A virus [5], Hepatitis 
B and C viruses [6, 7] and encephalomyocarditis virus 
[8], although by different mechanisms. We have shown 
that TRIM22 inhibited both basal and PMA (phorbol, 
12-myristate, 13-acetate) plus ionomycin-induced 
HIV-1 transcription, independently of its E3 ubiqui-
tin-ligase activity. Furthermore, TRIM22 did not affect 
either NF-kB or Tat-activated HIV-1 transcription [4]. 
As HIV-1 basal transcription is mainly driven by the 
transcription factor Sp1 that binds to the three bind-
ing sites present in the core enhancer of the U3 region 
in the HIV-1 LTR [9], we tested whether TRIM22 inter-
fered with Sp1-dependent transcription of HIV-1. For 
this purpose, Luciferase (Luc) -based reporter constructs 
driven by a minimal HIV-1 LTR (HIV-1 LTR Luc) con-
taining the TATA box, Tat-binding TAR sequences, and 
the three Sp1 sites (WT) were transfected in 293T cells, 
which are devoid of endogenous TRIM22 expression. To 
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determine whether TRIM22 inhibition of Sp1-dependent 
transcription was also related to the hierarchical cluster-
ing of the three Sp1 binding sites, HIV-1 LTR Luc dele-
tion/mutation variants that retained two (ΔSp1-III), one 
(ΔSp1-III +  II) and no Sp1 sites (mSp1) were tested in 
the presence and absence of TRIM22 expression. As 
these reporters contain two tet operator (tetO) sites for 
the binding of the doxycycline-inducible transcriptional 
activator rtTA [10], an rtTA-expressing plasmid was co-
transfected in 293T cells and transcription was activated 
by doxycycline added to the culture medium. The effect 
of TRIM22 was determined by co-transfecting 293T cells 
with either a TRIM22-expressing plasmid or the empty 
control plasmid pcDNA3.1(+).
In the absence of TRIM22 expression, the progressive 
deletion of the Sp1 binding sites significantly decreased 
HIV-1 transcription, whereas mutation of all three sites 
resulted in low but still detectable Luc levels. TRIM22 
expression significantly reduced Luc activity of the WT 
construct with three Sp1 binding sites (2.08 fold reduc-
tion; Fig.  1a). This inhibitory effect was less significant 
for the ΔSp1-III (1.89 fold) and ΔSp1-III + II (1.41 fold) 
constructs with two and one Sp1 sites, respectively, and 
absent for the mSp1 construct (1.05 fold) without Sp1 
sites. Thus, TRIM22 inhibited the Sp1-mediated tran-
scription of HIV-1 LTR and this inhibition correlated 
with the number of Sp1 sites and all three sites appear to 
be required for maximal inhibition.
To verify whether TRIM22 could inhibit Sp1-mediated 
transcription activation out of the context of the HIV-1 
LTR, a reporter construct driven by two tetO sites cou-
pled to the minimal cytomegalovirus (CMV) promoter 
and lacking any HIV-1 related promoter sequence 
(tetO-CMV configuration) was tested in the presence 
or absence of TRIM22-expressing plasmid. As shown in 
Fig. 1b, TRIM22 expression did not affect the Luc activ-
ity driven by tetO-CMV promoter. A similar promoter 
construct that included the three HIV-1 Sp1 binding 
sites (tetO-CMV-Sp1 configuration) was also tested. The 
presence of Sp1 binding sites increased the Luc activ-
ity  ~  fourfold and, importantly, restored the inhibitory 
effect of TRIM22 on promoter-dependent transcription. 
All together, these findings demonstrate that TRIM22 
expression inhibits Sp1-driven transcription from the 
HIV-1 LTR.
Next, we assessed whether TRIM22 inhibition of Sp1-
driven transcription could be observed in the context of 
full-length replication-competent HIV-1. We took advan-
tage of different HIV-rtTA infectious molecular clones 
that use the incorporated tetracycline-controlled (Tet-
On) gene expression system for activation of transcrip-
tion and that allow replication with alternative promoter 
configurations [10, 12]. In the “wild-type” HIV-rtTA 
strain, the Tat/TAR transcription mechanism was inac-
tivated through mutation of TAR, the rtTA gene was 
inserted at the site of the nef gene and tetO elements 
were inserted between the NF-kB and Sp1 sites in the U3 
promoter region. To test whether TRIM22 targeted Sp1, 
we included two variants with either the tetO-CMV or 
tetO-CMV-Sp1 promoter configuration [11]. Viral stocks 
were generated by transfecting 293T cells with the DNA 
of the three infectious clones and virion production was 
quantified by measuring the reverse transcriptase (RT) 
activity. Equal amounts of RT activity were used to infect 
human CD4+ SupT1 cells that had been transduced with 
a lentiviral vector expressing a shRNA against TRIM22 
(TRIM22-KD cells) or with a non-silencing control vec-
tor (CTRL-KD cells). As shown in Fig.  2a, transduction 
with the shRNA-TRIM22 vector efficiently knocked 
down TRIM22 RNA expression. Upon infection of the 
TRIM22-KD and CTRL-KD SupT1 cells with the differ-
ent HIV-rtTA variants, virus replication was followed up 
to 32 days post-infection (PI).
HIV-rtTA replicated more efficiently in TRIM22-
KD cells than in CTRL-KD cells (Fig.  2b). In this virus, 
three Sp1 sites are present in the U3 promoter region, 
which explains why TRIM22 negatively influences viral 
replication. The tetO-CMV virus did not show any rep-
lication upon infection of CTRL-KD and TRIM22-KD 
SupT1 cells, which is likely due to the absence of NF-kB 
and Sp1 binding sites (Fig. 2c). The tetO-CMV-Sp1 virus 
replicated also very poorly in CTRL-KD cells (RT activ-
ity became detectable only from day 29 PI), but it rep-
licated significantly better in the TRIM22-KD SupT1 
cells (Fig. 2d). Altogether, these results demonstrate that 
TRIM22 interferes with HIV-1 replication that is depend-
ent on Sp1 binding sites in the LTR.
As TRIM22 is an E3 ubiquitin ligase [8] and poly-ubiq-
uitination targets Sp1 to proteasome-dependent degra-
dation [13], we investigated whether TRIM22 expression 
resulted in the degradation of Sp1. However, Sp1 expres-
sion was not altered by TRIM22 transfection (Fig.  3a), 
which is consistent with our previous observation that 
TRIM22 inhibition of HIV-1 transcription is independent 
of its E3 ubiquitin ligase [4] and indicates that TRIM22 
does not promote Sp1 degradation. Then we evaluated 
whether an alteration of Sp1 phosphorylation, known 
to regulate Sp1-dependent transcriptional activity [14], 
could explain TRIM22 inhibition of Sp1-driven transcrip-
tion. As shown in Fig.  3b, the level of phosphorylated 
Sp1 was not altered by TRIM22 expression (lanes 2 and 
3). Shrimp Alkaline Phosphatase (SAP) treatment caused 
the disappearance of the phosphorylated forms of Sp1 
(upper band), without affecting overall Sp1 levels detected 
between TRIM22-overexpressing and control conditions 
(lanes 5 and 6). The analysis of nuclear extracts prepared 
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in the absence or presence of SAP by two-dimensional 
protein gel electrophoresis confirmed that TRIM22 did 
not cause an alteration of Sp1 phosphorylation state (data 
not shown). Furthermore, co-immunoprecipitation (co-
IP) experiments showed that endogenous Sp1 did not 
co-precipitate with TRIM22 in 293T cells transfected 
with a TRIM22 expressing plasmid (Fig. 3c) suggesting a 
lack of interaction between the two proteins.
We next tested whether TRIM22 influenced the in vitro 
binding of Sp1 to the DNA binding sites as present in 
a
b
Fig. 1 TRIM22 inhibits Sp1‑driven transcription. a 293T cells were seeded at 2.5 × 105 cells/ml in 96‑well plates. 24 h post‑seeding, 0.5 ng of the 
minimal LTR tetO Luc reporter (WT), two deletion mutants containing either two (ΔSp1‑III) or one (ΔSp1‑III+II) Sp1 binding sites and a mutant with 
a scrambled Sp1 sequence were co‑transfected in 293T cells together with rtTA‑V10 encoding plasmid (0.01 ng) [11] and either TRIM22‑expressing 
or empty control pcDNA3.1+ plasmids (5 ng). Transfected cells were cultured with doxycycline (1 µg/ml). Dual‑Glo Luciferase System (Promega) 
was used to determine the Firefly Luc activity 48 h post‑transfection according to the manufacturer’s instructions. The mean of five independent 
experiments ± SEM is reported. p values were calculated using two‑ways ANOVA. b Either tetO‑CMV or tetO‑CMV + Sp1 were co‑transfected in 
293T cells together with a TRIM22‑expressing plasmid, or a pcDNA3.1(+) plasmid as a control. rtTA‑V10 encoding plasmid was co‑transfected and 
the cells were cultured with doxycycline. Luc activity was assessed 48 h post‑transfection by a Luc assay. The mean of three independent experi‑
ments ± SEM is shown. The p values were calculated using the two‑ways ANOVA





Fig. 2 TRIM22 inhibits Sp1‑driven replication. a SupT1 cells were transduced with either pLKO.1/TRIM22shRNA (TRIM22‑KD) or pLKO.1/randomshRNA 
silencing control (CTRL‑KD) lentiviral vectors and selected in culture by the addition of puromycin (0.2 µM). TRIM22 expression was assessed by 
absolute quantitative real‑time PCR and normalized on the total number of 18S mRNA copies [4]. Specificity of TRIM22 knockdown was previously 
assessed [5]. Replication of the wild‑type (b), tetO‑CMV (c) and tetO‑CMV‑Sp1 (d) HIV‑rtTA virus variants in TRIM22‑KD and CTRL‑KD SupT1 cell 
lines. Virus stocks were generated by transfection of 293T cells with DNA of the infectious clone. Cells were cultured in the presence of doxycycline 
(1 µg/mL) and virus‑containing supernatant was harvested after 48 h and tested for Mg2+‑dependent reverse transcriptase (RT) activity assay [4] 
yielding measurable amounts of RT activity (~4000 cpm/µL). Viral supernatants containing 1 × 104 cpm‑equivalents were added to 5 × 105 SupT1 
TRIM22‑KD or KD‑control cells and spinoculated at 2900 rpm for 2 h at 37 °C. Cells were cultured at 5 × 105 cell/well in duplicate in the presence of 
doxycycline (1 µg/mL). Kinetics of viral replication were measured by RT activity assay in the supernatant collected every 3–4 days post‑infection (PI) 
up to 32 days. Mean ± SEM of three independent infections in triplicates are shown
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the HIV-1 LTR. For this purpose, a 293T cell line sta-
bly expressing TRIM22 (TRIM22-KI) and its control 
(2CTRL-KI) were generated by lentiviral transduction. As 
expected, TRIM22-KI or CTRL-KI cells expressed similar 
level of Sp1 as compared with mock-transduced 293T cells 
(Fig.  4a). However, when incubated with a DNA probe 
containing the three Sp1 binding sequences of the HIV-1 
LTR, the whole cell extract of TRIM22-KI cells either 
prepared in the absence (Fig. 4b) or in the presence (not 
shown) of phosphatase inhibitors showed a significant 
reduction (~77 %) of Sp1 binding as compared with con-
trol cells. In contrast, the binding of the unrelated constitu-
tively expressed transcription factor Oct-1 to its consensus 
sequence was not altered by TRIM22 expression. These 
findings demonstrate that TRIM22 specifically reduces the 
binding of Sp1 to its target DNA sequences in vitro.
Next, we performed chromatin IP (ChIP) on 293T cells 
transfected with an HIV-1 LTR-Luc plasmid in the presence 
or absence of a Flag-TRIM22 expression plasmid to further 
analyze the impact of TRIM22 on Sp1 binding to the viral 
promoter in the context of the complete HIV-1 LTR in vivo. 
IP was performed using anti-Sp1 and anti-Flag Abs to iso-
late Sp1-bound and TRIM22-bound DNA, respectively. 
The DNA released from the immune-complexes was ana-
lyzed by two independent quantitative real-time PCR that 
generated amplicons between −103/+14 (LTR promoter 
[15]) and +164/+244 (leader region [16]), respectively, rel-
ative to the transcription start site (+1). The LTR promoter 
PCR encompasses the three Sp1 binding sites whereas the 
leader region PCR is nearby two Sp1 binding sites. The rate 
of amplification was normalized on cross-linked non-IP 
chromatin (% of input). As expected, analysis of the Sp1-IP 
samples revealed reduced binding of the HIV-1 DNA in the 
presence of TRIM22, confirming that TRIM22 interferes 
with Sp1 binding to the HIV-1 LTR (Fig. 4c). In contrast, 
when the anti-Flag Ab was used to IP TRIM22 or when 
unrelated immunoglobulins (IgGs) were used as negative 
control, a similar low level of LTR fragments was detected 
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Fig. 3 TRIM22 does not interact with Sp1 and does not alter Sp1 
expression and phosphorylation. a 293T cells were transfected with 
1.5, 3, 4.5, or 6 µg of a TRIM22‑expressing plasmid, equalizing the DNA 
doses with empty pcDNA3.1(+) vector. 48 h post‑transfection, whole 
cell extract (WCE) was analyzed by western blotting with anti‑Sp1, 
anti‑TRIM22 and anti‑Actin antibodies (Abs). A similar level of Sp1 was 
observed in the mock‑treated cells, control cells (empty pcDNA3.1 
only) and cells expressing increasing concentration of TRIM22 
expressing plasmid. One representative of three independent experi‑
ments is shown. b 293T cells were transfected with 6 µg of either a 
TRIM22‑expressing plasmid (T22) or pcDNA3.1(+) plasmid (ctrl). 48 
h post‑transfection, WCE was prepared in the presence of PhosStop 
phosphatase inhibitor cocktail (Roche). An aliquot of 50 µg was 
treated with 5 I.U. of SAP (Roche) for 45 min at 37 °C and subjected to 
western blot analysis. The level of phosphorylated Sp1 was not altered 
by TRIM22 expression (lanes 2 and 3). SAP treatment caused the disap‑
pearance of the phosphorylated forms of Sp1 (upper band), without 
affecting overall Sp1 levels detected between TRIM22‑expressing 
and control conditions (lanes 5 and 6). One representative of two 
independent experiments is shown. c 293T cells were transfected 
with either TRIM22‑expressing or Luc‑expressing plasmid as unrelated 
control protein. 24 h post‑transfection, 90 % of WCE was immunopre‑
cipitated 2 h at 4 °C with anti‑TRIM22 (Abnova) Ab, whereas a 10 % vol‑
ume was saved as input fraction. Immunocomplexes were captured 
using magnetic Dynabeads protein G (Life Technologies), according 
to the manufacturer’s protocol. Western blotting was performed with 
anti‑Sp1 (Millipore), anti‑Firefly Luciferase (Millipore) and anti‑Actin 
Abs. Endogenous Sp1 did not immunoprecipitate with TRIM22. One 
representative of two independent experiments is shown
▸
Page 6 of 8Turrini et al. Retrovirology  (2015) 12:104 
Overall, these results demonstrate that TRIM22 causes 
transcriptional repression of HIV-1 by interfering with 
the binding of Sp1 to the HIV-1 LTR promoter region. 
Consistent with the lack of DNA binding domains in 
TRIM proteins [17], we did not observe direct binding of 
TRIM22 to the HIV-1 LTR. These observations together 
with our inability to co-IP TRIM22 and Sp1 suggest an 
indirect effect of TRIM22 on Sp1 binding to the HIV-1 
LTR, which may involve one or several other factors. 
This/these unidentified TRIM22 partner(s) could either 
promote a transcriptionally silenced heterochromatin 
configuration, as in the case of COUP-TF interacting 
protein 2 (CTIP2) [15] and c-Myc [18], or stimulate post-
translational modifications of Sp1, as previously sug-
gested for histone deacetylases (HDAC) [19] and p300 
[20], thereby affecting its DNA-binding affinity. Fur-
thermore, by preventing Sp1 binding to the promoter, 
TRIM22 might favor binding of Sp3, another Sp family 
member considered a repressor of transcription [21].
Sp1 is an ubiquitous factor and TRIM22 is expressed 
in different immune cells and induced by type I inter-
ferons [22]. Therefore, TRIM22 has the potential to 
a















































Fig. 4 TRIM22 prevents Sp1 binding to the HIV‑1 promoter. a 293T cells were transduced with either pAIP/TRIM22 (TRIM22‑KI) or pAIP/empty 
(CTRL‑KI) lentiviral vectors [4] and selected in culture by the addition of puromycin (0.5 µM). WCE from 50 × 106 mock‑transduced, CTRL‑KI and 
TRIM22‑KI cells was incubated overnight at 4 °C with 40 pmol of 5′‑biotinilated double‑stranded DNA probes containing either the three Sp1 bind‑
ing sites of the HIV‑1 LTR (as shown in Fig. 1a) or the consensus site of Oct‑1 (5’‑TGTCGAATGCAAATCACTAGAA‑3’). Each sample was pulled‑down 
using streptavidin‑conjugated beads (Life Technologies) and analyzed by western blot in parallel with the input fraction (1 % of the pull‑down) 
using anti‑TRIM22 (Sigma‑Aldrich), anti‑Sp1 and anti‑Actin (Santa Cruz Biotechnologies) Abs. One representative of three independent experi‑
ments is shown. b The Sp1 band intensity of the input and LTR‑pull‑down fractions from either CTRL‑KI or TRIM22‑KI cells was quantified by 
ImageJ. The mean ± SD of three independent experiments is reported. p value was calculated using a paired T test. c Modified pREP10 episomal 
vector containing the Luc reporter driven by the HIV‑1 LTR [15] was co‑transfected in 1.2 × 108 293T cells with Flag‑TRIM22‑expressing plasmid 
(provided by Dr. Nadir Mechti, Montpellier, France [8]) or empty plasmid. 48 h post‑transfection, proteins were crosslinked to the DNA by formal‑
dehyde incubation. Cell extracts were sonicated to shear chromatin obtaining an average fragment size ranging from 50 to 400 base pairs. IP was 
performed by using anti‑Flag (Sigma‑Aldrich), anti‑Sp1 and anti‑IgG (Santa Cruz Biotechnologies) Abs. Both input (1/1000) and immunoprecipitated 
DNAs were reverse‑crosslinked, purified from proteins and quantified by two real‑time SYBR‑Green qPCR (LTR promoter and leader region). LTR 
promoter primer sequences: for 5′‑GACTTTCCGCTGGGGACTTTC‑3′, rev 5′‑CTAACCAGAGAGACCCAGTAC‑3′. Leader region primer sequences: for 
5′‑TGGAAAATCTCTAGCAGTGGC‑3′, rev 5′‑GAGTCCTGCGTCGAGAGATCT‑3′. The amount of immunoprecipitated DNA was normalized to the input 
DNA and expressed as percentage on input fraction. The mean ± SEM of 3 independent experiments is shown. The p value was determined by the 
two‑way ANOVA
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inhibit the transcription of several host genes driven by 
Sp1 and to suppress cellular or even tumor growth [23]. 
Recent work has highlighted the peculiar configuration 
of the three adjacent Sp1 binding sites of the HIV-1 pro-
moter as a guanine-rich sequence that can fold into a 
G-quadruplex (G4) structure [24] previously identified 
in eukaryotic oncogenes [25]. Pharmacological stabili-
zation of this structure promotes transcription silenc-
ing of both the HIV-1 LTR [24] and oncogenes [25]. By 
preventing Sp1 binding, TRIM22 could favor the forma-
tion of the G4 structure in the HIV-1 LTR but also in 
oncogenes.
In conclusion, in the present study we demonstrate that 
TRIM22 acts as a negative regulator of HIV-1 replication 
via inhibition of basal Sp1-driven proviral transcription. 
We can thus speculate that TRIM22 favors either the 
establishment or maintenance of HIV-1 latency. TRIM22 
could therefore represent a novel target for pharmaco-
logical interference in latently infected cells harboring 
replication-competent proviruses.
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